BIO · NYSE · STOCK
Bio-Rad Laboratories (BIO) Stock Analysis
$355.44
52W $236.73 – $365.00
58/100
$9.59B
42.8
1.05
Is BIO Bullish or Bearish?
Mixed.
Innellis AI committee rates Bio-Rad Laboratories (BIO) Watch with a composite score of 58/100
, based on 6 analysts with 83% agreement.
Last updated August 17, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +2.36 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -17.64 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull & Bear Case
Bull Case
- Price-to-book of 1.1x is a discount to asset value — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Low leverage (debt-to-equity 0.16) -- balance sheet can absorb a shock — Risk
Bear Case
- P/E of 43.5 is expensive by classic value standards — Value
- ROE of only 3.1% -- cheap may mean cheap for a reason — Value
- EPS declining -29.6% YoY despite any revenue growth — Growth
- RSI at 70 is in overbought territory — Technical
- Weekly RSI at 79 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 24.0% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 17, 2026
Overall Committee Score
58/100
Agreement
83%
Analysts
6
Conviction
High
Sector Rank
Top 61%
of 192 Healthcare peers
Value Analyst
neutral
50
/ 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ Price-to-book of 1.1x is a discount to asset value
− P/E of 43.5 is expensive by classic value standards
Growth Analyst
neutral
48
/ 100 · High confidence
Moderate growth -- present but not remarkable
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
− EPS declining -29.6% YoY despite any revenue growth
Technical Analyst
neutral
58
/ 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− RSI at 70 is in overbought territory
Risk Analyst
neutral
58
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.16) -- balance sheet can absorb a shock
− Bollinger bandwidth of 24.0% signals elevated volatility
Macro Analyst
bullish
80
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
neutral
52
/ 100 · Moderate confidence
News flow is mixed or quiet -- no strong signal either way right now
+ News sentiment is positive (+0.33 across 21 articles, 14d)
− Negative filing: Costs associated with exit or disposal (restructuring) (13d ago)
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2963.04)
Investment Thesis Evolution
Committee score moved marginally from 57.6 to 57.6.
- New bearish signals: 2 appeared.
- Bearish pressure eased: 2 signal(s) disappeared.
Analyst-level changes:
- News Analyst: +1 bearish signal(s).
- Portfolio Manager: +1 bearish signal(s).
Comparing 2026-08-16 to 2026-08-17 (1 day apart).
Technical Analysis
RSI (14)
70.4
Overbought
MACD Histogram
1.952
Bullish Momentum
Trend Direction
Uptrend
Weekly: Sideways
Market Structure
Hh Hl
Support
$345.56
Resistance
$359.15
Bollinger %B
0.79
Inside Bands
Price vs Moving Averages
EMA 9
$351.09
Above
EMA 21
$336.00
Above
EMA 50
$316.41
Above
EMA 200
$296.49
Above
Fundamental Analysis
Valuation
67
Growth
68
Profitability
61
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio
42.8×
P/B Ratio
1.33×
PEG Ratio
-0.15
Dividend Yield
0.00%
52W High
$365.00
52W Low
$236.73
Quality & Growth
ROE
1019.5%
ROA
718.5%
Gross Margin
5189.8%
Operating Margin
907.6%
Revenue Growth YoY
—
Debt / Equity
0.17
AI Fundamental Assessment
P/E ratio of 42.8 (rich relative to a 15-40x range); Price-to-book of 1.3x; PEG ratio of -0.1 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 10.2%; Return on assets of 7.2%; Net margin of 8.6%; Gross margin of 51.9%; Current ratio of 3.14 (healthy short-term liquidity); Debt-to-equity of 0.17; Free cash flow per share is positive (13.20); Most recent quarter beat estimates by 48.4%; EPS growth accelerating (-24.7% -> +38.6% QoQ); Average YoY EPS growth of 0.4%; Analyst estimates falling over recent quarters
Get the Full BIO Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →